DEKKERS MARIJN E
Known title: DirectorCIK: 0001216068
Associated companies
Transaction History
| DNA | ▲ Buy | Option Exercise | 105,263 | — | 6/12/2024 | View on chart |
| DNA | ▼ Sell | Open Market | 265,000 | $220K | 5/16/2024 | View on chart |
| DNA | ▼ Sell | Open Market | 1,727,056 | $1.6M | 5/14/2024 | View on chart |
| DNA | ▼ Sell | Open Market | 171,455 | $439K | 11/3/2022 | View on chart |
| DNA | ▲ Buy | Grant | 70,921 | $0 | 6/10/2022 | View on chart |
| DNA | ▲ Buy | Grant | 1,746,706 | $0 | 3/11/2022 | View on chart |
| DNA | ▲ Buy | Grant | 374,960 | — | 9/16/2021 | View on chart |
| DNA | ▲ Buy | Grant | 5,780,364 | — | 9/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Analysts Reassess AI Demand, Lift Ginkgo Bioworks Fair Value
Analysts have updated their view on Ginkgo Bioworks, raising its fair value after a renewed focus on AI applications in biotechnology. TD Cowen kept a hold rating but lifted its target price to $11, reflecting optimism about the company’s growth prospects. The stock has been trading below its 52‑week low and fell more than the broader market, suggesting investors are still cautious.
Analysts Reassess AI Demand, Lift Ginkgo Bioworks Fair Value. Analysts have updated their view on Ginkgo Bioworks, raising its fair value after a renewed focus on AI applications in biotechnology. TD Cowen kept a hold rating but lifted its target price to $11, reflecting optimism about the company’s growth prospects. The stock has been trading below its 52‑week low and fell more than the broader market, suggesting investors are still cautious.